Fakih Marwan
Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Expert Rev Anticancer Ther. 2008 Sep;8(9):1471-80. doi: 10.1586/14737140.8.9.1471.
Over the past 10 years, healthcare providers involved in the management of metastatic colorectal cancer (MCRC) have seen an explosion in new agents and their combinations. These developments have resulted in an expansion in the options of care for MCRC patients and in a significant improvement in their overall survival. This article reviews the current role of anti-EGFR monoclonal antibodies in the management of MCRC and the identification of recent markers of response that lead towards treatment individualization.
在过去10年中，参与转移性结直肠癌（MCRC）管理的医疗服务提供者见证了新药物及其组合的激增。这些进展使得MCRC患者的治疗选择得以扩展，其总生存期也有了显著改善。本文综述了抗表皮生长因子受体（EGFR）单克隆抗体在MCRC管理中的当前作用，以及近期有助于实现治疗个体化的疗效标志物。
